SAB Biotherapeutics (NASDAQ:SABS) Rating Reiterated by HC Wainwright

SAB Biotherapeutics (NASDAQ:SABS)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a research note issued to investors on Tuesday, Benzinga reports. They currently have a $6.00 target price on the stock. HC Wainwright’s target price would suggest a potential upside of 27.66% from the company’s previous close.

Separately, Chardan Capital restated a “buy” rating and set a $25.00 target price on shares of SAB Biotherapeutics in a report on Tuesday.

SAB Biotherapeutics Stock Up 2.0 %

NASDAQ:SABS traded up $0.09 during mid-day trading on Tuesday, hitting $4.70. 2,650 shares of the company’s stock traded hands, compared to its average volume of 15,944. The company has a debt-to-equity ratio of 0.06, a quick ratio of 5.45 and a current ratio of 5.45. The firm’s 50 day simple moving average is $4.98 and its 200 day simple moving average is $3.09. SAB Biotherapeutics has a 1 year low of $4.00 and a 1 year high of $14.50.

Hedge Funds Weigh In On SAB Biotherapeutics

Hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new position in shares of SAB Biotherapeutics in the 3rd quarter valued at $28,000. State Street Corp lifted its holdings in shares of SAB Biotherapeutics by 244.2% during the 1st quarter. State Street Corp now owns 42,341 shares of the company’s stock valued at $159,000 after acquiring an additional 30,041 shares in the last quarter. Renaissance Technologies LLC acquired a new position in shares of SAB Biotherapeutics during the 2nd quarter valued at $45,000. Millennium Management LLC acquired a new position in shares of SAB Biotherapeutics during the 2nd quarter valued at $93,000. Finally, HighTower Advisors LLC acquired a new position in shares of SAB Biotherapeutics during the 4th quarter valued at $44,000. Institutional investors and hedge funds own 7.82% of the company’s stock.

SAB Biotherapeutics Company Profile

SAB Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at infectious diseases and immune and autoimmune disorders, including infectious diseases, influenza, CDI, type 1 diabetes, organ transplantation, and oncology, as well as immunology, gastroenterology, and respiratory diseases.